Literature DB >> 27343096

Implications of Oxygen Homeostasis for Tumor Biology and Treatment.

Boyan K Garvalov1, Till Acker2.   

Abstract

Tumors serve as a prototype system to study the role of the hypoxic microenvironment and gain insight in the regulation oxygen homeostasis. A series of biochemical and cell biological studies have significantly extended our knowledge of how tumor cells activate key regulatory mechanisms of oxygen homeostasis not only to adapt to the hostile tumor microenvironment but also to acquire a more aggressive tumor phenotype. Reduced oxygen levels and tumor-specific genetic alterations synergistically drive tumor progression by activating a key transcriptional system, the hypoxia inducible factors (HIFs). HIFs trigger a set of adaptive responses commonly associated with tumor malignancy including tumor angiogenesis, a shift in metabolism, proliferation, invasion, and metastasis. We and others could demonstrate that cancer stem cells are controlled by HIFs within a hypoxic niche, establishing an intriguing link between the well known function of hypoxia in tumor growth and stem cell biology. Additionally, HIF activation potentially conveys resistance to current tumor therapies including the evasive resistance phenotype observed after anti-angiogenic treatment. Together, these findings provide strong evidence that activation of the HIF system is a decisive step in cancer progression that critically shapes therapy response and clinical outcome. Recent insight into the precise mechanisms of oxygen sensing and signalling has offered new promising and potentially selective strategies to counteract this crucial pathway.

Entities:  

Keywords:  Anti-angiogenesis; Cancer stem cells (CSCs); Epithelial mesenchymal transition (EMT); Glioblastoma; Hypoxia; Hypoxia inducible factor (HIF); Prolyl hydroxylase (PHD); Tumor therapy

Mesh:

Substances:

Year:  2016        PMID: 27343096     DOI: 10.1007/978-1-4899-7678-9_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

2.  From Tissue Physoxia to Cancer Hypoxia, Cost-Effective Methods to Study Tissue-Specific O2 Levels in Cellular Biology.

Authors:  Carlos H V Nascimento-Filho; Alexandra T Glinos; Yeejin Jang; Eny M Goloni-Bertollo; Rogerio M Castilho; Cristiane H Squarize
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

3.  Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.

Authors:  Youliang Wu; Dapeng Yun; Yingjie Zhao; Yuqi Wang; Ruochuan Sun; Qiang Yan; Shangxin Zhang; Mingdian Lu; Zhen Zhang; Daru Lu; Yongxiang Li
Journal:  Oncotarget       Date:  2017-01-03

4.  Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway.

Authors:  Xueran Chen; Shangrong Zhang; Zhen Wang; Fengsong Wang; Xinwang Cao; Quan Wu; Chenggang Zhao; Huihui Ma; Fang Ye; Hongzhi Wang; Zhiyou Fang
Journal:  J Exp Clin Cancer Res       Date:  2018-06-28

5.  Bufalin induces DNA damage response under hypoxic condition in myeloma cells.

Authors:  Eri Fujii; Yuki Inada; Misaki Kakoki; Nao Nishimura; Shinya Endo; Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Toshiya Sugimoto; Hiroyuki Hata
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

Review 6.  Hypoxia‑inducible factors in hepatocellular carcinoma (Review).

Authors:  Yang Guo; Zunqiang Xiao; Liu Yang; Yuling Gao; Qiaojuan Zhu; Linjun Hu; Dongsheng Huang; Qiuran Xu
Journal:  Oncol Rep       Date:  2019-11-01       Impact factor: 3.906

7.  MiR-887 Promotes the Progression of Hepatocellular Carcinoma via Targeting VHL.

Authors:  Wei Zou; Jun Cheng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.